China 
Africa 
Explore chapters and articles related to this topic
The Past, Present, and Future of Digital Therapeutics
Published in Oleksandr Sverdlov, Joris van Dam, Digital Therapeutics, 2023
Sarah Cronin, Sophie Madden, Laura Ardill, Kate O'Reilly, Alette Brinth, Chandana Fitzgerald, Tess Huss
DTx is also rapidly evolving in the oncology space. While there have been significant recent advances in cancer therapies, many patients continue to experience debilitating and disabling symptoms, in addition to the unwieldy side effects of cancer medication. Integrating electronic patient-reported outcomes (ePROs) into routine cancer care has been shown to improve patient-clinician communication, patient satisfaction, symptom management, and control, as well as improve the QoL of many patients (Mooney et al., 2017; Basch et al., 2016). Voluntis' product Oleena was the first DTx broadly applicable to oncology and the first prescription DTx to receive marketing authorization from the FDA. It received positive reviews and a marketing authorization as a class II medical device exempted from 510(k) requirements under the 21st Century Cures Act.31,32 The mobile application provides tailored recommendations founded on evidence-based standards of care for symptom management in oncology, which have been validated by clinical experts. It plays a key role in addressing symptoms that can be managed but are often undertreated. MoovCare is another web-based patient-reported follow-up solution and is among the leaders in digital cancer care. This system collects patient data weekly and employs algorithms to measure the significance of findings and detect early recurrences. One trial reported an increase in survival by 7.6 months at a two-year follow-up (Denis et al., 2017).
Digital Health Technologies and Innovations
Published in Kelly H. Zou, Lobna A. Salem, Amrit Ray, Real-World Evidence in a Patient-Centric Digital Era, 2023
Kelly H. Zou, Mina B. Riad, Shaantanu Donde, Joan van der Horn, Tarek A. Hassan
In healthcare, especially in drug development and comparative effectiveness research, there are various types of real-world evidene (RWE) generated from digital sources using health information technology, for example, sensors, monitoring devices, wearables, digital apps, electronic patient-reported outcomes (ePROs), and digital therapeutics (DTx). Such real-world data (RWD) can be big data when vast in quantity and multiple sources are combined (Zou et al., 2020a). In addition, other data sources include genomics, medical imaging, laboratory assays, texts, and physician notes (Zou et al., 2010). More broadly speaking, commonly used data sources to derive insights are insurance and medical claims, electronic health records (EHRs), patient surveys, health risk and status assessments, and patient behaviors and preferences (Capelleri et al., 2013; Alemayehu et al., 2017; Zou et al., 2020c). Methods such as artificial intelligence (AI), machine learning and deep learning are increasingly applied to harness RWD to generate insights with an impact from end-to-end of research and development, as well as in real-world settings (Katkade et al., 2018; Zou et al., 2020b).
Axial Spondyloarthritis
Published in Jason Liebowitz, Philip Seo, David Hellmann, Michael Zeide, Clinical Innovation in Rheumatology, 2023
Not only are new biomarkers and outcome measurement strategies welcome, but the way in which we conduct measurements may also look different in ten years. While there has generally been slow uptake of electronic patient-reported outcomes in practice, some practices are getting this to work.116 This has become particularly important as telemedicine use expands.
Time for patient reported outcomes assessment in routine hematology practice: the case of chronic myeloid leukemia
Published in Expert Review of Hematology, 2019
Fabio Efficace, Francesco Cottone
The expansion of information technology and ad-hoc web-based platforms have made the electronic administration of PRO (ePRO) measures a reality in many university and community-based hospitals and several options for their implementation are now available. Unlike the traditional paper–pencil data compilation, ePRO assessments record patients’ ratings into electronic databases making it possible to display, in real time, PRO scores to the physicians’ PC in easy interpretable results (for example in graphical formats). These web-platforms are very flexible allowing physicians to select the content and the frequency of PRO surveys adapting it to the specific clinical settings and patients’ needs. The most typical approach is that patients complete these brief surveys in the waiting room, and results are already readily available at the time of clinical consultation, providing a basis for discussing specific health issues (e.g. symptoms or functional limitations) in need of special attention.
Digital solution in the follow-up of early breast cancer a randomized study
Published in Acta Oncologica, 2023
Johanna Mattson, Maria Peltola, Paula Poikonen-Saksela, Terhi Hermanson, Jenny Their, Niilo Färkkilä, Risto Roine, Carl Blomqvist
HUS CCC developed an electronic patient-reported outcome (ePRO) digital solution for cancer patients together with a Finnish startup company. The Noona solution is a web-based application enabling patients to contact cancer nurses between pre-planned appointments and self-report symptoms or adverse events of treatments by completing ePROMs via a computer or smart mobile devices [11]. The nurse practitioners answer the questions digitally and send care instructions. The first module of the digital Noona solution was tailored for the follow-up of EBC.
Satisfaction with care and adherence to treatment when using patient reported outcomes to individualize follow-up care for women with early breast cancer – a pilot randomized controlled trial
Published in Acta Oncologica, 2020
Cathrine L. Riis, Pernille T. Jensen, Troels Bechmann, Sören Möller, Angela Coulter, Karina D. Steffensen
We conducted a pilot randomized controlled trial to evaluate patient’s satisfaction with an individualized follow-up care (IC) compared to standard follow-up care (SC). Electronic patient reported outcomes (ePROs) were collected in both groups, but only used actively to perform individualized care in the intervention group. In SC ePROs were solely collected as an outcome measure for the study. Figure 1 shows a timeline of the distribution of questionnaires in SC and IC.